scholarly journals Trabeculotomy Augmented by Postoperative Topical Medications vs. Trabeculectomy Augmented by Mitomycin C

10.5772/60089 ◽  
2016 ◽  
Author(s):  
Hiroshi Kobayashi
Keyword(s):  
Mitomycin C ◽  
Topical Medications

scholarly journals Trabeculectomy with mitomycin C for glaucoma secondary to emulsified silicone oil after pars plana vitrectomy: three-years follow up

2022 ◽  
pp. 1-1
Author(s):  
Ivan Marjanovic ◽  
Ranko Gvozdenovic ◽  
Marija Bozic ◽  
Vesna Maric ◽  
Milenko Stojkovic ◽  
...  
Keyword(s):  
Mitomycin C ◽  
Pars Plana Vitrectomy ◽  
Silicone Oil ◽  
Open Angle Glaucoma ◽  
Single Center ◽  
Glaucoma Medication ◽  
Surgical Success ◽  
Pars Plana ◽  
Topical Medications

Background/Aim: To evaluate the efficacy of trabeculectomy with mitomycin C (MMC) for lowering intraocular pressure (IOP) in patients with open angle glaucoma (OAG) secondary to emulsified silicone oil (SO) after pars plana vitrectomy. Methods: A single-center, prospective study was conducted, from December 2014 to December 2019, on 56 consecutive patients with an uncontrolled elevation of IOP after SO removal. The primary end-point was the IOP at the three-years follow-up visit. Complete surgical success was defined as an IOP ranging from 7 mmHg to 18 mmHg without glaucoma medication. Qualified success was defined as IOP ? 21 mmHg with one or two topical medications. Results: Fifty-six patients with mean (standard deviation) age of 56.6 (13.1) years had a mean baseline IOP of 42.3 (39.3 to 45.3) mmHg, which reduced to 18.6 (17.9 to 19.3) mmHg at 3 years after surgery (P < 0.0001). 17 (30.4%) eyes were classified as complete success, 21 (37,5%) as qualified success, and 18 (32.1%) as failure. In all treated patients, the number of antiglaucoma medications was significantly reduced from 2.85 (0.77) to 1.63 (0.62), p<0.0001. Conclusion: Trabeculectomy with MMC may be an option for lowering IOP in patients with OAG secondary to emulsified SO which was not controlled with maximum antiglaucomatous medical treatment.

scholarly journals Same-Site Deep Sclerectomy Re-Operation with Subconjunctival and Subscleral Collagen Matrix (Ologen™) and Minimal use of Mitomycin C

2019 ◽  
Vol 13 (1) ◽  
pp. 43-50
Author(s):  
Pablo Díaz-Aljaro ◽  
Jordi Loscos-Arenas ◽  
Pau Romera-Romero ◽  
Nevena Romanic-Bubalo ◽  
Stefano Grixolli-Mazzon ◽  
...  
Keyword(s):  
Mitomycin C ◽  
Collagen Matrix ◽  
Final Visit ◽  
Deep Sclerectomy ◽  
Prospective Evaluation ◽  
Safety And Efficacy ◽  
Surgical Success ◽  
Late Failure ◽  
Second Surgery ◽  
Topical Medications

Purpose:This study aimed to evaluate the safety and efficacy of same-site Deep Sclerectomy (DS) re-operation with subconjunctival and subscleral collagen matrix (Ologen™) and minimal use of mitomycin C in cases of late failure blebs.Methods:A prospective evaluation of consecutive patients on which same-site DS was performed with subconjunctival and subscleral collagen matrix (Ologen™) and minimal use of mitomycin C; all performed at a single university institution. Intraocular pressure (IOP), number of glaucoma medications, postoperative interventions, postoperative complications and surgical success were registered at 24 hours, 1, 6 and 12 months after the surgery.Results:Twenty-five eyes of 25 patients were included in this study. Time from first DS was 55.08 ± 28.16 months. Mean preoperative IOP was 20.88 ± 6.06 mmHg and it was reduced to 16.64 ± 4.02 mmHg, at 12 months after re-operation (p 0,007). At this final visit, requirements for topical medications dropped from a mean of 2.2 ± 1.0 to 0.72 ± 1.0 per patient and no medications were required in 60% of patients. Success was 36 % in criteria A (IOP ≤15mmHg), 72% in criteria B (IOP ≤18 mmHg) and 80 % in criteria C (IOP ≤15 mmHg), 12 months after the second surgery.Conclusion:The same-site DS re-operation with subconjunctival and subscleral collagen matrix (Ologen®) and minimal use of mitomycin C is a safe and adequate technique for the reduction of IOP, especially when targeted IOP is not lower than 15mmHg.

scholarly journals Utility of Collagen Matrix Insertion during Ahmed Valve Implantation with Adjunctive Mitomycin-C: Outcomes at One-year

2021 ◽  
Vol 62 (10) ◽  
pp. 1388-1396
Author(s):  
Yong Hyun Kim ◽  
Ko Eun Kim ◽  
Chungwoon Kim ◽  
Jae Hong Ahn
Keyword(s):  
Mitomycin C ◽  
Collagen Matrix ◽  
Tube Placement ◽  
Success Rates ◽  
Implant Surgery ◽  
Ahmed Valve ◽  
Surgical Failure ◽  
One Year ◽  
Valve Implantation ◽  
Topical Medications

Purpose: To compare the surgical outcomes of adjunctive mitomycin-C (MMC) Ahmed valve implantation with and without collagen matrix insertion.Methods: We retrospectively reviewed 108 eyes of 108 patients who underwent Ahmed valve implant surgery with adjunctive MMC. Collagen matrix insertion/Ahmed valve implant surgery (CM-AGV) was performed on 55 eyes, while conventional Ahmed valve implant surgery (AGV) was performed on 53 eyes. We defined surgical failure as an intraocular pressure (IOP) > 18 mmHg or <5 mmHg on two or more consecutive visits, regardless of medication status.Results: After surgery, the IOP and number of topical medications required fell significantly (compared with the preoperative period) in both groups (both p < 0.001); these findings did not significantly differ between groups. The cumulative surgical success rates at 1 year did not significantly differ between groups (78.2% vs. 79.2%, p = 0.54). The only risk factor significantly associated with surgical failure was a postoperative hypertensive phase. Anterior chamber (compared with sulcus) tube placement was significantly associated with visual acuity loss at 1 year postoperatively, but this did not significantly differ between groups.Conclusions: At the 1-year follow-up after Ahmed implant surgery with adjunctive MMC, the success rates of surgery with and without collagen matrix insertion were similar.

Topical medications on dermabraded tattoos

1970 ◽  
Vol 102 (4) ◽  
pp. 438-439
Author(s):  
R. D. Hagerman
Keyword(s):  
Topical Medications

1570: Combined Mitomycin C and Hyperthermia (SYNERGO) for Patients with Superficial Bladder Cancer (SBC) after Bacillus Calmette-Guerin (BCG) Failure

2007 ◽  
Vol 177 (4S) ◽  
pp. 519-519
Author(s):  
Ofer Nativ ◽  
Renzo Colombo ◽  
Dov Engelstein ◽  
Ofer N. Gofrit ◽  
Thomas Akkad ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Mitomycin C ◽  
Superficial Bladder Cancer ◽  
Bacillus Calmette Guerin ◽  
Bcg Failure

832: Optimized Intravesical Mitomycin C Treatment for Superficial Bladder Cancer: Long-Term Follow-Up

2006 ◽  
Vol 175 (4S) ◽  
pp. 268-269 ◽  
Author(s):  
Jessie L. Au ◽  
Robert A. Badalament ◽  
M. Guillaume Wientjes ◽  
Donn C. Young ◽  
Tong Shen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Mitomycin C ◽  
Superficial Bladder Cancer ◽  
Long Term Follow Up

Erste Ergebnisse – Die gedeckte Sklerotomie unter primärer Anwendung von Mitomycin C 0,02%

2008 ◽  
Vol 225 (S 04) ◽  
Author(s):  
E Karioris ◽  
C Wirbelauer ◽  
H Häberle ◽  
DT Pham
Keyword(s):  
Mitomycin C ◽  
Erste Ergebnisse

Lokale Applikation von Mitomycin C bei Atemwegsstenosen

Pneumologie ◽  
2009 ◽  
Vol 63 (S 01) ◽  
Author(s):  
PC Bauer ◽  
U Sommerwerck ◽  
J Hagmeyer ◽  
F Bonella ◽  
U Costabel
Keyword(s):  
Mitomycin C

Wundmodulation bei der gedeckten Sklerotomie durch Kombination von Mitomycin-C und subkonjunktivalem Avastin

2011 ◽  
Vol 228 (S 02) ◽  
Author(s):  
AM Hoang ◽  
A Berthold ◽  
A Just ◽  
DT Pham ◽  
C Wirbelauer
Keyword(s):  
Mitomycin C
Sign in / Sign up

Export Citation Format

Share Document